Kyle Carver Sells 18,175 Shares of Evommune (NYSE:EVMN) Stock

by · The Markets Daily

Evommune, Inc. (NYSE:EVMN – Get Free Report) CFO Kyle Carver sold 18,175 shares of Evommune stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $22.84, for a total value of $415,117.00. Following the completion of the transaction, the chief financial officer owned 59,335 shares in the company, valued at $1,355,211.40. This trade represents a 23.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Evommune Trading Down 5.1%

Shares of EVMN stock traded down $1.20 during midday trading on Monday, hitting $22.04. The company had a trading volume of 451,405 shares, compared to its average volume of 416,057. The stock has a 50 day simple moving average of $24.14. Evommune, Inc. has a 52-week low of $13.89 and a 52-week high of $33.20.

Evommune (NYSE:EVMN – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.19. As a group, equities analysts predict that Evommune, Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

EVMN has been the topic of several analyst reports. Evercore reiterated an “outperform” rating and issued a $55.00 target price on shares of Evommune in a research note on Tuesday, February 10th. Morgan Stanley lifted their target price on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Stifel Nicolaus assumed coverage on Evommune in a research note on Friday, May 1st. They issued a “buy” rating and a $54.00 price target on the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $48.00 price target on shares of Evommune in a research note on Friday, April 10th. Finally, Weiss Ratings assumed coverage on Evommune in a research note on Tuesday, February 3rd. They issued a “sell (e)” rating on the stock. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $49.25.

Read Our Latest Stock Report on EVMN

Institutional Trading of Evommune

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Evommune in the fourth quarter valued at approximately $34,000. Strs Ohio acquired a new position in Evommune during the first quarter worth $41,000. The Manufacturers Life Insurance Company acquired a new position in Evommune during the fourth quarter worth $179,000. XTX Topco Ltd acquired a new position in Evommune during the fourth quarter worth $321,000. Finally, Oxford Asset Management LLP acquired a new position in Evommune during the fourth quarter worth $335,000.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

Recommended Stories